PTO/SB/30 (10-01)

Approved for use through 10/31/2002, OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE to a collection of information unless it displays a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a

### REQUEST

# CONTINUED EXAMINATION (RCE) TRANSMITTAL

Commissioner for Patents **Box RCE** Washington, DC 20231

1000011 01		
Application Number	09/599,152	
Filing Date	June 21, 2000	
First Named Inventor	Yang, David	
Art Unit	1619	
Examiner Name	Jones, Dameron	
Attorney Docket Number	UTXC:664	

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2. Submission required under 37 CFR 1.114 a. Previously submitted Consider the amendment(s)/reply under 37 CFR 1.116 previously filed on (Any unentered amendment(s) referred to above will be entered). Consider the arguments in the Appeal Brief or Reply Brief previously filed on iii. Other b. Enclosed Information Disclosure Statement (IDS) ✓ Amendment/Reply Declaration filed 3/14/03 in SN 09/434.313 Other Affidavit(s)/Declaration(s) Miscellaneous a. Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a MONTHS. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required) b. Other Fees The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed. The Director is hereby authorized to charge the following fees, or credit any overpayments, to 50-1212/UTXC:664 Deposit Account No.\_ RCE fee required under 37 CFR 1.17(e) Extension of time fee (37 CFR 1.136 and 1.17) Other b. Check in the amount of \$\_ c. Payment by credit card (Form PTO-2038 enclosed) WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED 32,165 Registration No. (Attorney/Agent) Name 3/19/03 Date Signature CERTIFICATE OF MAILING OR TRANSMISSION I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissione Patents, Box RCE, Washington, DC 20231, or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below. VDavid LI Plenke Name (PrintiType) 3/19/03 Signature

Burden Hour Statement; This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Palent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND Fees and Completed Forms to the following address; Assistant Commissioner for Palents, Box RCE, Washington, DC 20231.

## FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP 600 CONGRESS AVENUE, SUITE 2400 AUSTIN, TEXAS 78701-3271 WWW.FULBRIGHT.COM

FAX RECEIVED JUL 22 2003 GROUP 1600

#### **FACSIMILE TRANSMISSION**

OFFICIAL

DATE:

July 22, 2003

MATTER NUMBER:

10020527

RECIPIENT:	FAX No.:	PHONE NO.:
Examiner Jones	703-308-4556	703-308-4640

FROM:

David L. Parker

USER ID:

DP01982

FLOOR:

20

PHONE:

(512) 536-3055

FAX:

(512) 536-4598

RE:

SN 09/599,152

NUMBER OF PAGES WITH COVER PAGE:

62

Message:

Per your request, enclosed is a copy of the RCE and accompanying documents we filed on March 19, 2003. Also enclosed is the stamped postcard showing receipt of these documents by the PTO on March 24, 2003.

If you need anything else, please feel free to contact me.

#### **CAUTION - CONFIDENTIAL**

THE INFORMATION CONTAINED IN THIS FACSIMILE IS CONFIDENTIAL AND MAY ALSO CONTAIN PRIVILEGED ATTORNEY-CLIENT INFORMATION OR WORK PRODUCT. THE INFORMATION IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHOM IT IS ADDRESSED. IF YOU ARE NOT THE INTENDED RECIPIENT, OR THE EMPLOYER OR AGENT RESPONSIBLE TO DELIVER IT TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY USE, DISSEMINATION, DISTRIBUTION OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THE FACSIMILE IN ERROR, PLEASE IMMEDIATELY NOTIFY US BY TELEPHONE, AND RETURN THE ORIGINAL MESSAGE TO US AT THE ADDRESS ABOVE VIA THE U.S. POSTAL SERVICE. THANK YOU.

> IF YOU DO NOT RECEIVE ALL OF THE PAGES, PLEASE CALL LORI BARNETT AT (512) 536-3073 AS SOON AS POSSIBLE.

Mailed: 3/19/03 Filed: Due Date:	Client: M. D. Anderson Cancer Center F&J File No.	Applicant: Yang et al. Attorney:	Title: ETHYLENEDICYSTEIN (EC)-DRUG CONJUGATES, COMPOSITIONS AND METHODS FOR TISSUE SPECIFIC DISEASE IMAGING	Serial No.: 09/599,152	IDENTIFICATION OF APPLICATION	Assignment Enclosed X Cert. of Timely Mailing Exp. Mail:	and references A13 and C146)	xtension of Time: Declaration: S	Response to Office Action Dated:	Specification: Pages H // Drawings: Sheets	Continuation CPA CPA Divisional CPA	Foreign priority already claimed un	New Application For: Priority Date:	Please indicate receipt of the below-identified paper:
1/28/03	lo.: UTXC:664	DLP	FOR TISSUE SPECIFIC			ail:	CLLI THIN THE COM	ntal IDS (with form 1440	Final Rejection					